Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Innovent Biologics (IVBXF)
OTHER OTC:IVBXF
RESEARCH TOOLSreports
Holding IVBXF?
Track your performance easily
IVBXF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.83 - $7.02
Previous Close$4.96
Volume380.00
Average Volume (3M)20.61K
Market Cap
$8.10B
Enterprise Value$7.51B
Total Cash (Recent Filing)¥7.03B
Total Debt (Recent Filing)¥2.77B
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Mar 26, 2025EPS Estimate
-$0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares OutstandingN/A
10 Day Avg. Volume1,617
30 Day Avg. Volume20,614
Standard Deviation0.19
R-Squared0.00016
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6.90Price Target Upside42.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Innovent Biologics News
PremiumCompany Announcements
Innovent Biologics Ends Proposed Subscription Agreement
PremiumCompany Announcements
Innovent Biologics Reports Strong Revenue Growth in Q3 2024
PremiumCompany Announcements
Innovent Biologics Sells Minority Stake in Subsidiary
PremiumCompany Announcements
Innovent’s Psoriasis Drug Application Accepted in China
PremiumCompany Announcements
Innovent Biologics Grants Shares to Employees
PremiumCompany Announcements
Innovent Biologics Announces Board Reshuffle
PremiumCompany Announcements
Innovent Biologics Reveals Board and Committee StructureOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
10.59% Mutual Funds
― Other Institutional Investors
82.44% Public Companies and
Individual Investors
IVBXF FAQ
What was Innovent Biologics’s price range in the past 12 months?
Innovent Biologics lowest stock price was $3.83 and its highest was $7.02 in the past 12 months.
What is Innovent Biologics’s market cap?
Currently, no data Available
When is Innovent Biologics’s upcoming earnings report date?
Innovent Biologics’s upcoming earnings report date is Mar 26, 2025 which is in 123 days.
How were Innovent Biologics’s earnings last quarter?
Innovent Biologics released its earnings results on Aug 28, 2024. The company reported -$0.033 earnings per share for the quarter, beating the consensus estimate of -$0.035 by $0.001.
Is Innovent Biologics overvalued?
According to Wall Street analysts Innovent Biologics’s price is currently Undervalued.
Does Innovent Biologics pay dividends?
Innovent Biologics does not currently pay dividends.
What is Innovent Biologics’s EPS estimate?
Innovent Biologics’s EPS estimate is -$0.03.
How many shares outstanding does Innovent Biologics have?
Innovent Biologics has 1,637,909,800 shares outstanding.
What happened to Innovent Biologics’s price movement after its last earnings report?
Innovent Biologics reported an EPS of -$0.033 in its last earnings report, beating expectations of -$0.035. Following the earnings report the stock price went down -2.182%.
Which hedge fund is a major shareholder of Innovent Biologics?
Currently, no hedge funds are holding shares in IVBXF
---
Innovent Biologics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.74%
12-Months-Change
Fundamentals
Return on Equity
-11.09%
Trailing 12-Months
Asset Growth
13.37%
Trailing 12-Months
Company Description
Innovent Biologics
Innovent Biologics, Inc. is an investment company, which engages in the development and manufacture of biopharmaceutical products. Its products include sintilimab (IBI-308), a novel PD-1 antibody; IBI-305, the bevacizumab (Avastin) biosimilar; IBI-301, the rituximab (MabThera/Rituxan) biosimilar; and IBI-303, the (Humira) biosimilar. The company was founded by De Chao Yu, Kevin Chen, and Scott M. Wheelwright on April 28, 2011 and is headquartered in Suzhou, China.
---
IVBXF Stock 12 Month Forecast
Average Price Target
$6.90
▲(42.27% Upside)
Technical Analysis
Best Analysts Covering IVBXF
1 Year
1 Year Success Rate
4/6 ratings generated profit
1 Year Average Return
+2.25%
reiterated a buy rating 19 days ago
Copying Jill Wu's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +2.25% per trade.
---